Efficacy and safety of sorafenib in patients with advanced clear-cell renal-cell carcinoma (RCC) with bone metastases: results from the phase III TARGET study

被引：0
|
作者：
Gschwend, J. E. [1 ]
Bukowski, R. [2 ]
Eisen, T. [3 ]
Stadler, W. S. [4 ]
Szczylik, C. S. [5 ]
Oudard, O. S. [6 ]
Siebels, M. S. [7 ]
Michel, M. S. [8 ]
Grimm, M. O. [9 ]
Escudier, B. E. [10 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin & Poliklin, Munich, Germany
[2] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA
[3] Cambridge Res Inst, Cambridge, England
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Mil Med Acad, Warsaw, Poland
[6] Hop Euopeen Georges Pompidou, Paris, France
[7] LMU, Klinikum Grosshadern, Munich, Germany
[8] Univ Klinikum Mannheim, Mannheim, Germany
[9] Klinikum Carl Gustav Carus, Dresden, Germany
[10] Inst Gustave Roussy, Villejuif, France
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：130 / 131
页数：2
相关论文
共 50 条
  • [41] Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.
    Puzanov, Igor
    Sosman, Jeffrey Alan
    Santoro, Armando
    Martell, Robert E.
    Dy, Grace K.
    Goff, Laura Williams
    Ma, Wen Wee
    Fetterly, Gerald J.
    Michael, Shaunita A.
    Means-Powell, Julie Ann
    Chai, Feng
    Lamar, Maria
    Strauss, Gary M.
    Zucali, Paolo A.
    Chiang, Wendy M.
    Jarboe, Jamie
    Schwartz, Brian E.
    Adjei, Alex A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice
    Thiery-Vuillemin, Antoine
    Cholley, Tiphaine
    Calcagno, Fabien
    Hugues, Marion
    Maurina, Tristan
    Limat, Samuel
    Thierry Nguyen Tan Hon
    Almotlak, Hamadi
    Mouillet, Guillaume
    Nerich, Virginie
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : E297 - E305
  • [43] Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients
    Fernandes, Flavia Goncalves
    Silveira, Henrique Cesar Santejo
    Junior, Joao Neif Antonio
    da Silveira, Rosana Antunes
    Zucca, Luis Eduardo
    Carcano, Flavio Mavignier
    Sanches, Andre Octavio Nicolau
    Neder, Luciano
    Scapulatempo-Neto, Cristovam
    Serrano, Sergio Vicente
    Jonasch, Eric
    Reis, Rui Manuel
    Evangelista, Adriane Feijo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (05) : 1 - 14
  • [44] Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study
    Kim, Sung Han
    Kim, Sohee
    Nam, Byung-Ho
    Lee, Sang Eun
    Kim, Choung Soo
    Seo, Ill Young
    Kim, Tae Nam
    Hong, Sung-Hoo
    Kwon, Tae Gyun
    Seo, Seong Il
    Joo, Kwan Joong
    Song, Kanghyon
    Kwak, Cheol
    Chung, Jinsoo
    PLOS ONE, 2015, 10 (08):
  • [45] Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
    Shahani, Rohan
    Kwan, Kevin G.
    Kapoor, Anil
    DRUG HEALTHCARE AND PATIENT SAFETY, 2010, 2 : 85 - 91
  • [46] Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma
    Johns, Andrew C.
    Campbell, Matthew T.
    Gao, Mamie
    Hahn, Andrew W.
    Lim, Zita
    Wang, Emily
    Gao, Jianjun
    Shah, Amishi Y.
    Msaouel, Pavlos
    Tannir, Nizar M.
    ONCOLOGIST, 2024, 29 (07): : 589 - 595
  • [47] Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
    Hailiang Zhang
    Baijun Dong
    Jiade J Lu
    Xudong Yao
    Shilin Zhang
    Bo Dai
    Yijun Shen
    Yao Zhu
    Dingwei Ye
    Yiran Huang
    BMC Cancer, 9
  • [48] Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
    Zhang, Hailiang
    Dong, Baijun
    Lu, Jiade J.
    Yao, Xudong
    Zhang, Shilin
    Dai, Bo
    Shen, Yijun
    Zhu, Yao
    Ye, Dingwei
    Huang, Yiran
    BMC CANCER, 2009, 9
  • [49] Randomised phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 287 - 287
  • [50] Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma
    Motzer, Robert John
    Eisen, Timothy
    Hutson, Thomas E.
    Szczylik, Cezary
    Krygowski, Mizue
    Strahs, Andrew Louis
    Esteves, Brooke
    Krivoshik, Andrew P.
    Berkenblit, Anna
    Nosov, Dmitry
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345